Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer
Completed
Sanofi
Phase 3
The purpose of this clinical trial is to determine if RPR109881 is a better treatment than
capecitabine (Xeloda) for advanced breast cancer in patients that no longer benefit from
docetaxel and/or paclitaxel.
Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer
Completed
Sanofi
Phase 1/Phase 2
The goal of this phase I-II clinical research study is to find the highest safe dose of
XRP9881 and capecitabine that can be given in combination in the treatment of metastatic
breast cancer in patients who have been previously treated by taxanes and anthracyclines. The
safety and effectiveness of this combination will also be studied. Patients participating in
the study will be asked to give additional blood samples to look at the level of study drugs
in the blood.
XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
Completed
Sanofi
Phase 2
The primary objective of the study is to assess the activity of XRP9881 in combination with
trastuzumab.
The secondary objectives are safety and pharmacokinetic interaction
Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer
Completed
Sanofi
Phase 2
The purpose of this study is to evaluate the anti-tumor activity of the combination of
experimental drug (larotaxel) when combined with Herceptin® in patients with advanced breast
cancer. Anti-tumor activity will be determined by looking at changes in tumor size on CT or
MRI scans. Additional goals of this study are to look at patient safety, to determine how
long the study drugs (larotaxel and Herceptin®) stay in the patient's body and what effects
the study medications may have on each other, and to find out how long patients remain cancer
free on this study treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
